Dr. Scholz on Using Abiraterone in mCRPC

Video

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

The COU-AA-302 study demonstrated an unequivocal survival advantage for abiraterone compared to placebo, Scholz says. This is a revolutionary development, he adds, because the standard of care for this disease has been docetaxel.

In comparing abiraterone and docetaxel, Scholz finds there is equal efficacy. However, a substantial reduction in toxicity and convenience of administration exists in using abiraterone.

Almost universally within Prostate Oncology Specialists, patients with mCRPC are being treated with abiraterone prior to docetaxel, in light of these findings.

<<<

View more from the 2015 GU Cancer Symposium

Related Videos
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Daniel Spratt, MD
Daniel Spratt, MD
Philip J. Koo, MD
Patrick I. Borgen, MD
Anthony D'Amico MD, PhD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania